Rahul Rao, deputy director of Federal Trade Commission's Bureau of Competition, said the regulatory group’s tougher stance on pharmaceutical deals stems from a general view that market incentives in the sector had grown misaligned with competitive practices.
Key Takeaways
-
FTC Bureau of Competition Deputy Director Rahul Rao no seismic event lead to the agency’s recent actions on pharma deals.
“There wasn’t a seismic event that happened,” he said. “What we are seeing is greater consolidation. We’re seeing the effects...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?